7
May
2024

Quality Chemical Laboratories, LLC

Exhibitor at CPHI North America 2024 stand 1253
About Us

•Founded 1998 by Dr. Yousry Sayed •Privately owned •Science driven decision-making •Nimble, Responsive •“We do what is scientifically right and treat our clients as partners or extensions of QCL. If a client has a problem, QCL has a problem.” •FDA and DEA Registrations, 90,000 ft2 six facility campus, 250 employees, New construction of 100,000 ft2 • Analytical Development and Validation, FP and RM Analysis, Stability Studies, Custom Synthesis, Formulations, CTM manufacturing.

  • US
  • 2019
    On CPHI since
  • 3
    Certificates
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
Contract Service
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Analytical Services
Biopharmaceutical
Contract Manufacturer
Generic APIs producer
Laboratory Services
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
Contact info
Event information
CPHI North America 2024
  • 07 May 2024 - 09 May 2024
  • Pennsylvania Convention Center, Philadelphia
  • Visit us at stand 1253

Products Featured at CPHI North America 2024

  • Analytical Testing and Formulation Development

    Product Analytical Testing and Formulation Development

    Quality Chemical Laboratories is known for its capabilities in the development and validation of analytical methods for raw materials, drug substances, and drug products. With a strong focus on quality and precision, QCL employs cutting-edge technologies and a highly skilled team of scientists to offer com...

Quality Chemical Laboratories Resources (1)

  • Whitepaper Rapid, Science-Driven Success in Early Phase Pharmaceutical Development

    THE CHALLENGE: Develop at least one dosage form that avoids first-pass metabolism in the gut and all analytical methods using a limited quantity API. THE STRATEGY: This program began with typical quality by design elements including excipient compatibility studies and API characterization allowing formulations development personnel to select the right excipients for initial prototype development. In fact, one excipient caused an API stability problem. Since the excipient compatibility study design was binary, the stability issue was easily isolated to a single excipient and eliminated from future formulation inclusion.